Home > Inhibitors & Agonists > Cytoskeleton/Cell Adhesion Molecules > Integrin
Cat. No. Product name CAS No.
DC9487 Arg-Gly-Asp-Ser

Arg-Gly-Asp-Ser(RGDS peptide) is an integrin binding sequence that inhibits integrin receptor function; decreases systemic inflammation via inhibition of collagen-triggered activation of leukocytes and attenuates expression of inflammatory cytokines, iNOS

91037-65-9
DC11178 BIO1211

BIO1211 (BIO-1211) is a potent, highly specific integrin α4β1 (VLA-4) inhibitor with Kd/IC50 of 20 pM/4 nM for the activated form of α4β1.

187735-94-0
DC9278 CWHM-12

CWHM-12 a novel small molecule inhibitor of αV integrins with IC50s of 1.8/0.8/1.5/0.2 nM for αvβ1/αvβ3/αvβ8; less potency on αvβ5(IC50=61 nM) and on inhibition on αIIbβ3/α2β1/α10β1.

1564286-55-0
DC8055 cyclo(-RGDfK)

cyclo(-RGDfK,-Arg-Gly-Asp-D-Phe-Lys)) is a selective αvβ3-integrin antagonist.

161552-03-0
DC8399 Cyclo(RGDyK)

Cyclo(RGDyK) is a potent and selective αVβ3 integrin inhibitor with IC50 of 20 nM.

250612-42-1
DC11177 DS-70

DS-70 (α4 integrin inhibitor DS-70) is a novel potent α/β- peptidomimetic antagonist of α4 integrin, binds to integrin α4β1 with nanomolar affinity.

DC8224 Lifitegrast(SAR 1118)

SAR 1118 is a potent tetrahydroisoquinoline (THIQ)-derived LFA-1/ICAM-1 antagonist for treating dry eye.

1025967-78-5
DC9489 Tirofiban (hydrochloride monohydrate)

Tirofiban hydrochloride monohydrate is a potent non-peptide, glycoprotein IIb/IIIa (integrins alphaIIbbetaIII) antagonist

150915-40-5
DC7327 Tirofiban(L700462;MK383)

Tirofiban(L700462;MK383) is a potent non-peptide, glycoprotein IIb/IIIa (integrins alphaIIbbetaIII) antagonist.

144494-65-5
DC7777 Valategrast (R411)

Valategrast (R411), a small molecule antagonist of α4β1 integrin, represents a potential therapy for asthma

220847-86-9
DC9490 Zaurategrast

Zaurategrast(CDP-323) is an oral α4-integrin inhibitor.

455264-31-0
DC10034 GLPG0187

GLPG0187 is a small molecule integrin receptor antagonist (IRA) with potential antineoplastic activity.

1320346-97-1
DC28075 αvβ1 integrin-IN-1

αvβ1 integrin-IN-1 (Compound C8) is a potent and selective αvβ1 integrin inhibitor with an IC50 of 0.63 nM. Antifibrotic effects.

1689540-62-2
DC28176 BMS-688521

BMS-688521 is a highly potent, orally active inhibitor of the LFA-1/ICAM interaction, with an IC50 of 2.5 nM in the adhesion assay and an IC50 of 60 nM in the MLR assay. BMS-688521 is efficacious in a mouse allergic eosinophilic lung inflammation model.

893397-44-9
DC28249 Natalizumab

Natalizumab is a recombinant, humanized monoclonal antibody, binds to α4β1-integrin and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1). Natalizumab can be used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease. Natalizumab is also the first targeted therapy which blocks an essential mechanism for lymphocyte entry to the CNS and thus prevents acute demyelinating relapses.

189261-10-7
DC28280 c(phg-isoDGR-(NMe)k) TFA

c(phg-isoDGR-(NMe)k) TFA is a selective and potent α5β1-integrin ligand with an IC50 of 2.9 nM.

DC29131 α2β1 Integrin Ligand Peptide (TFA)

α2β1 Integrin Ligand Peptide TFA interacts with the α2β1 integrin receptor on the cell membrane and mediates extracellular signals into cells. It is a potential antagonist of collagen receptors.

DC29134 Risuteganib hydrochloride

Risuteganib hydrochloride is a synthetic RGD (arginyl-glycyl-aspartic acid)-class peptide. Risuteganib hydrochloride is an anti-integrin that downregulates oxidative stress and restores homeostasis, and targets three integrin receptors that are implicated in dry age-related macular degeneration (AMD) in order to restore homeostasis in the retina.

Page 1 / Total 1 FirstPrevNextLastGoto